|Articles|May 21, 2014

Digital Technology: A Double-Edged Sword

Author(s)Guest Blogger

Technology offers the promise of engaging patients on a level never seen before.

Technology offers the promise of engaging patients on a level never seen before. The benefits of an engaged patient start with increased compliance-a great thing for pharmaceutical companies-and extend to a more active and empowered consumer of healthcare, and ultimately to better and more affordable outcomes.

But technology is a double-edged sword. Its increasing complexity leads to increasing risk and greater scrutiny.

So what does this mean to Senior Directors and Franchise Leaders at pharmaceutical companies? In this Pharm Exec article, Scott Hansen and Geogg Melick explain why it’s vital to get that technology working right first time.


Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.